Novartis India Ltd. (BSE: 500672) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹4,693 Cr, it ranks #875 by market cap among the 6,137 Indian listed companies on FinBizNet, and #17 of 63 in Pharmaceuticals. At ₹1,824.50 (as of 25 Oct 2026), the share price is 29.5% below its 52-week high of ₹2,588.80 and 171.4% above its 52-week low of ₹672.25.
| Current Price | ₹1,824.50 |
|---|---|
| Market Cap | ₹4,693 Cr |
| BSE Code | 500672 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 51.4 |
| Return on Equity | 11.63% |
| Return on Assets | 6.13% |
| 52-Week Range | ₹672.25 – ₹2,588.80 |
| 3-Month Price Change | +11.2% |
| Beta (1Y) | -0.06 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.novartis.in |
| Revenue | ₹104 Cr |
|---|---|
| Net Profit | ₹32 Cr |
| Net Margin | 31.0% |
| EPS (Basic) | ₹13.05 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Novartis India Limited is involved in the pharmaceutical business in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. Novartis India Limited was incorporated in 1947 and is headquartered in Mumbai, India. The company is a subsidiary of Novartis AG.
1. Pharmaceutical Business-This segment offers drugs and pharmaceutical products. 2. Generics-0 3. OTC-0 4. Animal Health-0
1. Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Novartis India Ltd. | ₹4,693 Cr | 51.4 | 11.63% | ₹104 Cr | — |
Listed by market capitalisation. Ratios are shown for context only.
Novartis India Ltd. is trading at ₹1,824.50, with a market capitalisation of ₹4,693 Cr.
Novartis India Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Novartis India Ltd. has a P/E of 51.4 and a return on equity of 11.63%.
Novartis India Ltd. is listed on the BSE under the scrip code 500672.
In Q1 FY27, Novartis India Ltd. reported revenue of ₹104 Cr and net profit of ₹32 Cr, with basic EPS of ₹13.05 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.